285 related articles for article (PubMed ID: 34196511)
1. Intra-heterogeneity in transcription and chemoresistant property of leukemia-initiating cells in murine Setd2
Song J; Du L; Liu P; Wang F; Zhang B; Xie Y; Lu J; Jin Y; Zhou Y; Lv G; Zhang J; Chen S; Chen Z; Sun X; Zhang Y; Huang Q
Cancer Commun (Lond); 2021 Sep; 41(9):867-888. PubMed ID: 34196511
[TBL] [Abstract][Full Text] [Related]
2. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease.
Risueño RM; Campbell CJ; Dingwall S; Levadoux-Martin M; Leber B; Xenocostas A; Bhatia M
Blood; 2011 Jun; 117(26):7112-20. PubMed ID: 21562049
[TBL] [Abstract][Full Text] [Related]
3. A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms.
Griessinger E; Anjos-Afonso F; Pizzitola I; Rouault-Pierre K; Vargaftig J; Taussig D; Gribben J; Lassailly F; Bonnet D
Stem Cells Transl Med; 2014 Apr; 3(4):520-9. PubMed ID: 24493855
[TBL] [Abstract][Full Text] [Related]
4. CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling.
Fang X; Chen C; Xia F; Yu Z; Zhang Y; Zhang F; Gu H; Wan J; Zhang X; Weng W; Zhang CC; Chen GQ; Liang A; Xie L; Zheng J
J Hematol Oncol; 2016 Nov; 9(1):124. PubMed ID: 27855694
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
[TBL] [Abstract][Full Text] [Related]
6. Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia.
Sumitomo Y; Koya J; Nakazaki K; Kataoka K; Tsuruta-Kishino T; Morita K; Sato T; Kurokawa M
Blood; 2016 Sep; 128(12):1614-24. PubMed ID: 27480114
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
[TBL] [Abstract][Full Text] [Related]
8. Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
Kagoya Y; Yoshimi A; Kataoka K; Nakagawa M; Kumano K; Arai S; Kobayashi H; Saito T; Iwakura Y; Kurokawa M
J Clin Invest; 2014 Feb; 124(2):528-42. PubMed ID: 24382349
[TBL] [Abstract][Full Text] [Related]
9. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract][Full Text] [Related]
10. WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target.
Zhou B; Jin X; Jin W; Huang X; Wu Y; Li H; Zhu W; Qin X; Ye H; Gao S
J Transl Med; 2020 Jun; 18(1):254. PubMed ID: 32580769
[TBL] [Abstract][Full Text] [Related]
11. SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
Dong Y; Zhao X; Feng X; Zhou Y; Yan X; Zhang Y; Bu J; Zhan D; Hayashi Y; Zhang Y; Xu Z; Huang R; Wang J; Zhao T; Xiao Z; Ju Z; Andreassen PR; Wang QF; Chen W; Huang G
Leukemia; 2019 Nov; 33(11):2585-2598. PubMed ID: 30967619
[TBL] [Abstract][Full Text] [Related]
12. Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression.
Stetson LC; Balasubramanian D; Ribeiro SP; Stefan T; Gupta K; Xu X; Fourati S; Roe A; Jackson Z; Schauner R; Sharma A; Tamilselvan B; Li S; de Lima M; Hwang TH; Balderas R; Saunthararajah Y; Maciejewski J; LaFramboise T; Barnholtz-Sloan JS; Sekaly RP; Wald DN
Leukemia; 2021 Oct; 35(10):2799-2812. PubMed ID: 34244611
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow niche ATP levels determine leukemia-initiating cell activity via P2X7 in leukemic models.
He X; Wan J; Yang X; Zhang X; Huang D; Li X; Zou Y; Chen C; Yu Z; Xie L; Zhang Y; Liu L; Li S; Zhao Y; Shao H; Yu Y; Zheng J
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33301426
[TBL] [Abstract][Full Text] [Related]
14. [NF-κB activity in myeloid leukemia stem cells].
Kagoya Y
Rinsho Ketsueki; 2015 Apr; 56(4):384-91. PubMed ID: 25971268
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
Hein N; Cameron DP; Hannan KM; Nguyen NN; Fong CY; Sornkom J; Wall M; Pavy M; Cullinane C; Diesch J; Devlin JR; George AJ; Sanij E; Quin J; Poortinga G; Verbrugge I; Baker A; Drygin D; Harrison SJ; Rozario JD; Powell JA; Pitson SM; Zuber J; Johnstone RW; Dawson MA; Guthridge MA; Wei A; McArthur GA; Pearson RB; Hannan RD
Blood; 2017 May; 129(21):2882-2895. PubMed ID: 28283481
[TBL] [Abstract][Full Text] [Related]
16. FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.
Wang L; Gao L; Xu S; Gong S; Chen L; Lü S; Chen J; Qiu H; Xu X; Ni X; Song X; Zhang W; Yang J; Liu M; Hu X; Wang J
J Hematol Oncol; 2013 Nov; 6(1):85. PubMed ID: 24517186
[TBL] [Abstract][Full Text] [Related]
17. A mitophagy inhibitor targeting p62 attenuates the leukemia-initiation potential of acute myeloid leukemia cells.
Li Y; Li Y; Yin J; Wang C; Yang M; Gu J; He M; Xu H; Fu W; Zhang W; Ru Y; Liu X; Li Y; Xin Y; Gao H; Xie X; Gao Y
Cancer Lett; 2021 Jul; 510():24-36. PubMed ID: 33862150
[TBL] [Abstract][Full Text] [Related]
18. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
[TBL] [Abstract][Full Text] [Related]
19. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
20.
Fu JF; Shih LY; Yen TH
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34080665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
